1. Home
  2. Labeler Index
  3. Hf Acquisition Co Llc, Dba Healthfirst
  4. 51662-1316
  5. NDC Package Code: 51662-1316-3 Dopamine Hydrochloride

NDC Package 51662-1316-3 Dopamine Hydrochloride

Injection, Solution Intravenous - View Billable Units, 11-Digit Format, RxNorm

Table of Contents

    1. Package Information
    2. NDC HCPCS Crosswalk
    3. Other Packages
    4. Frequently Asked Questions

Package Information

Find all the important details about this NDC Package code, including the 11-Digit NDC Billing number, billing units, wholesale price, RxNorm crosswalk, active ingredients, pharmacologic clasess, etc.

NDC Package Code:
51662-1316-3
Package Description:
12 POUCH in 1 CASE / 1 BAG in 1 POUCH (51662-1316-2) / 250 mL in 1 BAG
Product Code:
51662-1316
Proprietary Name:
Dopamine Hydrochloride
Non-Proprietary Name:
Dopamine Hydrochloride
Substance Name:
Dopamine Hydrochloride
Usage Information:
Dopamine Hydrochloride in 5% Dextrose Injection, USP is indicated for the correction of hemodynamic imbalances present in shock due to myocardial infarction, trauma, endotoxic septicemia, open heart surgery, renal failure and chronic cardiac decompensation as in refractory congestive failure.When indicated, restoration of circulatory volume should be instituted or completed with a suitable plasma expander or whole blood, prior to administration of dopamine hydrochloride.Patients most likely to respond to dopamine are those whose physiological parameters (such as urine flow, myocardial function and blood pressure) have not undergone extreme deterioration. Reports indicate that the shorter the time between onset of signs and symptoms and initiation of therapy with volume restoration and dopamine, the better the prognosis.Poor Perfusion of Vital Organs: Although urine flow is apparently one of the better diagnostic signs for monitoring vital organ perfusion, the physician also should observe the patient for signs of reversal of mental confusion or coma. Loss of pallor, increase in toe temperature or adequacy of nail bed capillary filling also may be observed as indices of adequate dosage. Reported studies indicate that when dopamine is administered before urine flow has decreased to approximately 0.3 mL/minute prognosis is more favorable.However, it has been observed that in some oliguric or anuric patients, administration of the drug has produced an increase in urine flow which may reach normal levels. The drug also may increase urine flow in patients whose output is within normal limits and thus may help in reducing the degree of pre-existing fluid accumulation. Conversely, at higher than optimal doses for a given patient, urinary flow may decrease, requiring a reduction of dosage. Concomitant administration of dopamine and diuretic agents may produce an additive or potentiating effect.Low Cardiac Output: Dopamine's direct inotropic effect on the myocardium which increases cardiac output at low or moderate doses is related to a favorable prognosis. Increased output has been associated with unchanged or decreased systemic vascular resistance (SVR). The association of static or decreased SVR with low or moderate increases in cardiac output is regarded as a reflection of differential effects on specific vascular beds, with increased resistance in peripheral beds (e.g., femoral), and concurrent decreases in mesenteric and renal vascular beds. Redistribution of blood flow parallels these changes so that an increase in cardiac output is accompanied by an increase in mesenteric and renal blood flow. In many instances the renal fraction of the total cardiac output has been found to increase. Increase in cardiac output produced by dopamine is not associated with substantial decreases in systemic vascular resistance as may occur with isoproterenol.Hypotension: Low to moderate doses of dopamine, which have little effect on SVR, can be used to manage hypotension due to inadequate cardiac output. At high therapeutic doses, dopamine's α-adrenergic action becomes more prominent and thus may correct hypotension due to diminished SVR. As in other circulatory decompensation states, prognosis is better in patients whose blood pressure and urine flow have not undergone extreme deterioration. Therefore, it is suggested the physician administer dopamine as soon as a definite trend toward decreased systolic and diastolic pressure becomes apparent.
11-Digit NDC Billing Format:
51662131603
NDC to RxNorm Crosswalk:
  • RxCUI: 1743877 - DOPamine HCl 1600 MCG/ML in 250 ML Injection
  • RxCUI: 1743877 - 250 ML dopamine hydrochloride 1.6 MG/ML Injection
  • RxCUI: 1743877 - dopamine HCl 1600 MCG/ML per 250 ML Injection
    • Product Type:
    Human Prescription Drug
    Labeler Name:
    Hf Acquisition Co Llc, Dba Healthfirst
    Dosage Form:
    Injection, Solution - A liquid preparation containing one or more drug substances dissolved in a suitable solvent or mixture of mutually miscible solvents that is suitable for injection.
    Administration Route(s):
  • Intravenous - Administration within or into a vein or veins.
    • Active Ingredient(s):
  • DOPAMINE HYDROCHLORIDE 1.6 mg/mL
    • Pharmacologic Class(es):
  • Catecholamine - [EPC] (Established Pharmacologic Class)
  • Catecholamines - [CS]
    • Sample Package:
    No
    FDA Application Number:
    NDA018826
    Marketing Category:
    NDA - A product marketed under an approved New Drug Application.
    Start Marketing Date:
    10-19-2018
    Listing Expiration Date:
    12-31-2025
    Exclude Flag:
    N
    Code Structure:

    The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

    * Please review the disclaimer below.

    NDC HCPCS Crosswalk

    This crosswalk is intended to help the public understand which drug products (identified by NDCs) are assigned to which HCPCS billing codes.

    NDC 51662-1316-3 HCPCS crosswalk information with package details and bill units information.

    NDC Billing CodeHCPCS CodeHCPCS Code Desc.DosagePackage SizePackage QuantityBillable UnitsBillable Units / Pkg
    51662131603J1265Dopamine injection40 MG2501210120

    * Please review the disclaimer below.

    Other Product Packages

    The following packages are also available for this product:

    NDC Package CodePackage Description
    51662-1316-1250 mL in 1 BAG

    * Please review the disclaimer below.

    Frequently Asked Questions

    What is NDC 51662-1316-3?

    The NDC Packaged Code 51662-1316-3 is assigned to a package of 12 pouch in 1 case / 1 bag in 1 pouch (51662-1316-2) / 250 ml in 1 bag of Dopamine Hydrochloride, a human prescription drug labeled by Hf Acquisition Co Llc, Dba Healthfirst. The product's dosage form is injection, solution and is administered via intravenous form.

    Is NDC 51662-1316 included in the NDC Directory?

    Yes, Dopamine Hydrochloride with product code 51662-1316 is active and included in the NDC Directory. The product was first marketed by Hf Acquisition Co Llc, Dba Healthfirst on October 19, 2018 and its listing in the NDC Directory is set to expire on December 31, 2025 if the product is not updated or renewed by the manufacturer.

    What is the 11-digit format for NDC 51662-1316-3?

    The 11-digit format is 51662131603. The 11-digit billing format might be required by the Centers for Medicare & Medicaid Services (CMS) and other payers in billing claim forms.

    This package code is originally configured in a 5-4-1 segment 10-digit format and by adding a zero within the original NDC package code we can obtain the converted 11-digit format in a 5-4-2 segment configuration. The table below shows the 11-digit code conversion:

    10-Digit Format10-Digit Original Code11-Digit Format11-Digit Code
    5-4-151662-1316-35-4-251662-1316-03